The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -110,635 | -126,502 | -120,613 |
| Stock-based compensation | 12,715 | 13,358 | 18,510 |
| Depreciation on property and equipment | 101 | 105 | 107 |
| Non-cash lease expense | 25 | 24 | 24 |
| Accounts receivable | -319 | 25 | -129 |
| Prepaid expenses and other current assets | -2,869 | -1,164 | -498 |
| Other assets | 38 | -167 | 1,361 |
| Accounts payable | 1,563 | -1,065 | -9,401 |
| Accrued expenses and other current liabilities | 756 | 10,259 | -5,304 |
| Net cash used in operating activities | -92,325 | -102,515 | -117,411 |
| Purchase of property and equipment | 0 | 0 | 0 |
| Net cash used in investing activities | 0 | 0 | 0 |
| Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions | 544,194 | - | - |
| Payment of offering costs | 586 | - | - |
| Proceeds from stock options exercised | 20,995 | 24,595 | 2,918 |
| Net cash provided by financing activities | 564,603 | 24,595 | 2,918 |
| Effect of exchange rate changes on cash and cash equivalents | 377 | 878 | -566 |
| Net change in cash and cash equivalents | 472,655 | -77,042 | -115,059 |
| Cash and cash equivalents at beginning of period | 521,870 | 713,971 | - |
| Cash and cash equivalents at end of period | 994,525 | 521,870 | - |
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)